AUS
NZ
UK
CA
USA
IND
Standard Biotools Inc. (NASDAQ:LAB) announced that Chief Financial Officer Kim Hanjoon Alex completed a stock withholding transaction involving 202,476 common shares on July 23, 2026. This transaction was conducted to satisfy tax obligations arising from the vesting of restricted stock units granted in August 2025. The shares were withheld at a price of $0.895 per share, and post-transaction, the CFO retained direct beneficial ownership of 2,563,054 common shares.
Key Points
- NASDAQ ticker: LAB
- CFO Kim Hanjoon Alex withheld 202,476 shares for mandatory tax purposes on July 23, 2026
- Transaction price set at $0.895 per share; CFO continues to hold 2,563,054 shares beneficially
- Shares withheld to fulfill tax liabilities from RSU vesting granted in August 2025
Restricted Stock Unit Vesting Triggers Tax Withholding
Standard Biotools clarified that the share disposition by CFO Kim Hanjoon Alex was an automatic withholding transaction, not a voluntary sale. The shares were withheld to cover tax withholding obligations triggered by the vesting of restricted stock units originally granted on August 1, 2025. This RSU grant was previously reported in a Form 4 filing with the Securities and Exchange Commission dated August 5, 2025, establishing the transaction’s initial terms and date.
When executives receive compensation through RSUs that vest, tax liabilities arise at the vesting date. Companies commonly fulfill these tax obligations by withholding a portion of vested shares at fair market value, covering federal, state, and local taxes. This method streamlines tax compliance and prevents executives from needing to sell shares manually.
Details of the Share Withholding Transaction and Valuation
The transaction involved withholding 202,476 shares of Standard Biotools common stock on July 23, 2026, at a price of $0.895 per share, reflecting the fair market value at vesting. This valuation corresponds to the vesting date rather than the original grant date in August 2025, demonstrating a fixed price point for the withholding event.
The transaction was executed on a direct ownership basis, with the CFO maintaining direct beneficial ownership throughout. No indirect ownership or third-party arrangements were disclosed. This direct ownership reporting aligns with typical insider transactions involving company officers.
Post-Transaction Beneficial Ownership Status
After the withholding transaction, CFO Kim Hanjoon Alex retained beneficial ownership of 2,563,054 shares of Standard Biotools common stock on a direct basis. This substantial equity stake remains unchanged as of the disclosure date, underscoring ongoing alignment between executive management and shareholders. Insider ownership levels are closely monitored by investors and analysts as indicators of management confidence and governance quality.
Participation in Employee Stock Purchase Plan
The CFO’s beneficial ownership total includes 5,000 shares acquired under Standard Biotools’ Employee Stock Purchase Plan (ESPP) on May 29, 2026. This demonstrates the CFO’s engagement with the company’s employee equity programs alongside the RSU compensation. The ESPP shares were acquired prior to the July 23, 2026 withholding transaction, and both share categories are aggregated in the SEC filing. Details such as purchase price or discount for the ESPP transaction were not disclosed.
Officer Certification and Legal Representation
The Form 4 filing was signed on July 27, 2026, three business days after the transaction date, by Tomone Tanaka, attorney-in-fact for CFO Kim Hanjoon Alex. Delegation of signing authority to legal counsel is standard practice for insider filings and does not affect the filing’s validity. The CFO’s position subjects the transaction to Section 16 reporting requirements, ensuring ongoing public disclosure of future securities transactions.
Insider Reporting Compliance for Standard Biotools
As a NASDAQ-listed company (ticker LAB), Standard Biotools adheres to Section 16 of the Securities Exchange Act of 1934, requiring officers and significant shareholders to file Forms 4 within two business days of security transactions. This filing reflects compliance, providing transparency on insider equity changes and executive compensation activities.
The July 2026 transaction adds to the public record of executive equity dealings at Standard Biotools, enabling investors and analysts to assess management’s equity interests and insider trading compliance. Such disclosures are mandatory and critical for evaluating governance and strategic shareholding patterns.
Standard Tax Withholding Practice in Executive Compensation
The automatic share withholding to satisfy tax obligations is a common feature in RSU programs at public companies. This "net settlement" approach avoids the need for executives to sell shares to cover taxes, simplifying administration and reducing risk of securities law violations during restricted trading periods.
The withholding relates specifically to the August 1, 2025 RSU grant vesting, with the tax event and share withholding occurring within the same reporting period, eleven months after the grant. Such vesting schedules support long-term retention and alignment of executives with shareholder interests.
SEC Insider Trading Rules and Timely Reporting
The filing complies with SEC Rule 16a-3, mandating insider beneficial ownership changes be reported within two business days. The July 27, 2026 filing date meets this requirement following the July 23, 2026 transaction. Timely Form 4 submissions are essential for regulatory compliance and investor transparency.
The detailed disclosure includes transaction codes, pricing, and ownership totals, enabling regulatory verification and public scrutiny. The explicit link between the withholding transaction and the original RSU grant establishes a clear audit trail, consistent with SEC expectations and fostering investor confidence in disclosure integrity.
